RGX-365 Ginsenoside Mixture for Fine Dust Respiratory Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for an effective composition and method to prevent or treat fine dust-induced respiratory diseases, as existing treatments are inadequate for addressing the inflammatory responses and health impacts caused by fine dust exposure.
Innovation Solution
A composition comprising a mixture (RGX-365) of ginsenosides Rg2, Rg4, and Rh1, prepared by reacting ginsenoside Re with distilled water under high temperature and pressure, followed by column separation, to enrich these ginsenosides and enhance their therapeutic effects on respiratory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ginsenoside Re is reacted with distilled water under high temperature and pressure to produce ginsenosides Rg2, Rg4, Rg6, and Rh1, then the therapeutic effect on fine dust-induced respiratory diseases is improved, but the manufacturing complexity and process control difficulty increase
Solution Approach 1:
The patent applies parameter changes by optimizing specific reaction conditions including temperature (110-140°C), pressure (0.11-0.16 MPa), and reaction time (4-6 hours) to convert ginsenoside Re into the desired mixture of ginsenosides Rg2, Rg4, Rg6, and Rh1. These controlled parameter changes enable consistent production of the therapeutic mixture while managing process complexity
Solution Approach 2:
The patent creates a composite ginsenoside mixture (RGX-365) containing multiple specific ginsenosides (Rg2, Rg4, Rg6, and Rh1) in defined ratios. This composite approach combines the therapeutic benefits of individual ginsenosides to enhance overall effectiveness against fine dust-induced respiratory diseases
2Manufacturing precision
If a mixture containing multiple ginsenosides (Rg2, Rg4, Rg6, Rh1) is prepared through column separation, then the purity and specificity of active ingredients are improved, but the manufacturing time and production cost increase
Solution Approach 1:
The patent uses column separation to extract and isolate specific ginsenosides (Rg2, Rg4, Rg6, and Rh1) from the reaction mixture. This extraction process removes impurities and unwanted components, achieving high purity of the therapeutic active ingredients while concentrating the desired ginsenosides
Solution Approach 2:
The patent segments the complex reaction mixture into individual ginsenoside components through column separation. This segmentation allows for precise control of each ginsenoside's concentration and purity, enabling the creation of a standardized therapeutic mixture with defined composition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RGX-365 mixture effectively reduces inflammation, permeability, and reactive oxygen species generation in lung tissues, providing a selective therapeutic benefit for fine dust-induced respiratory diseases.
Implementation Method 1
reacting ginsenoside Re with distilled water under high temperature and pressure
Implementation Method 2
followed by column separation, to enrich these ginsenosides
Data Source
AI summary
The present invention relates to a composition, for preventing or treating a fine dust-induced respiratory disease, comprising a mixture (Rgx 365), comprising ginsenosides Rg2, Rg4, Rg6 and Rh1, as an active ingredient, a preparation method thereof, and a functional health food, for preventing or relieving a fine dust-induced respiratory disease, comprising same. The present invention exhibits excellent effects on permeability reduction, reactive oxygen (ROS) generation reduction, leucocyte reduction and cytokine generation reduction in a model for fine dust-induced inflammatory response, and thus can be utilized for preventing and treating a fine dust-induced respiratory disease.